NEUPATH HEALTH ANNOUNCES VOTING RESULTS FROM THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS AND ISSUANCE OF STOCK OPTIONS AND RESTRICTED SHARE UNITS
15 Jun 2023
TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 14, 2023 and the grant of stock options (“Options”) and restricted share units (“RSUs”). All figures are in Canadian dollars, unless otherwise noted.
The results of the director elections were as follows:
Name
Votes in
Favour
% Votes in
Favour
Votes
Withheld
% Votes
Withheld
Jolyon Burton
25,903,046
99.98%
5,000
0.02%
Daniel Chicoine
25,681,546
99.13%
226,500
0.87%
Sasha Cucuz
25,681,546
99.13%
226,500
0.87%
Dan Legault
25,681,546
99.13%
226,500
0.87%
Joseph Walewicz
25,695,546
99.18%
212,500
0.82%
The shareholders of the Company also voted: (i) to set the number of directors of the Corporation for the ensuing year at five (5), and that the directors be authorized to set the number of directors within the maximum and minimum numbers provided for in the articles of the Corporation by way of resolution; (ii) to reappoint Ernst & Young LLP, Chartered Professional Accounts, Licensed Public Accountants, as auditors of the Company for the ensuing year, and (iii) to approve the Company’s amended and restated stock option plan in the form attached as Schedule “A” to the management information circular dated April 25, 2023 prepared in connection with the Meeting.
Issuance of Stock Options and Restricted Share Units
On June 15, 2023, NeuPath granted 296,806 stock options (“Options”) to non-executive directors of the Company at an exercise price of $0.16 per share, with an expiry date of June 15, 2030. The Options are subject to time-based vesting and will fully vest on June 15, 2024.
In addition, on June 15, 2023, the Company granted 98,938 RSUs to the same non-executive directors of the Company. The RSUs are subject to time-based vesting in accordance with the policies of the TSX Venture Exchange. RSUs granted will fully vest on June 15, 2024. The terms of the RSUs are in accordance with the Company’s Amended and Restated Restricted Share Unit Plan approved by shareholders at the 2022 AGM.
Directors of the Company are entitled to receive an annual equity grant as part of their compensation package. As there was no equity award made to these directors for their 2022 services, the current grant has been increased to reflect equity compensation for both the current year and the missed 2022 grant.
About NeuPath
NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual we treat to live their best life.
NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.